All loans, advances, which are of a non-trade nature, due to and from the related parties are expected to be settled before the Listing.
Financial Information · p. 421
It is the view of our Directors that our transactions with related parties during the Track Record Period was conducted on an arm's length basis and with normal commercial terms between the relevant parties.
The amounts due from related parties are non-trade in nature and are expected to be settled before the Listing.
Financial Information · p. 360
We enter into transactions with our related parties from time to time during our ordinary course of business and on terms comparable to the terms of transactions with other entities that are not related parties, details of which are set forth in Note 32 of the Accountants' Report.
Financial Information · p. 380
Our Directors believe that each of the related party transactions set out in Note 32 to the Accountants' Report was conducted on an arm's-length basis and would not distort our track record results or make our historical results not reflective of our future performance.
During the Track Record Period, we had one transaction with a related party in accordance with the terms agreed with the counterparty.
Financial Information · p. 546
Our Directors confirm that the material related party transaction during the Track Record Period was conducted on an arm's length basis, and would not distort our results of operations over the Track Record Period or make our historical results over the Track Record Period not reflective of our expectations for our future performance.
All of the aforementioned amounts due from Mr. Luo were provided by our Group to facilitate his repurchase of Shenzhen Ningyuan’s shares from other shareholders through himself and his two controlled companies, Heyuan Chuangye and Weikang Yuanju.
Financial Information · p. 501
The loan agreement will be terminated prior to the Listing.
Financial Information · p. 502
Our subsidiary, Shenzhen Ningyuan, provided an unsecured loan of RMB4.5 million to a Shareholder in January 2024 to address the Shareholder’s short-term liquidity needs.
Amounts due to related parties, which are non-trade in nature, relate to the 2021 Reorganization.
Financial Information · p. 381
As of December 31, 2022, 2023 and 2024, March 31, 2025 and July 31, 2025, our amounts due to related parties were RMB334.3 million, RMB340.1 million, RMB335.3 million, RMB5.3 million (US$0.7 million) and nil, respectively.
Financial Information · p. 397
Our Directors believe that our transactions with related parties during the Track Record Period were conducted on an arm’s length basis, and they did not distort our results of operations or make our historical results not reflective of our future performance.
As our business scale expanded, we acquired the trademarks of DAHON from DNA at a consideration of USD2.2 million determined with reference to the appraise value of the trademarks to facilitate our brand building.
Financial Information · p. 271
As of December 31, 2022, 2023 and 2024 and April 30, 2025, amounts due from DNA recognized as either amounts due from related parties or trade receivables were RMB19.2 million, RMB7.2 million, RMB4.6 million and RMB4.6 million, respectively.
Financial Information · p. 271
Our Directors believe that our transactions with related parties during the Track Record Period, which were trade in nature, were conducted on an arm’s length basis, and they did not distort our results of operations or make our historical results not reflective of our future performance.
For the years ended December 31, 2022, 2023, 2024 and the three months ended March 31, 2024 and 2025, we procured components, materials and property management services from entities controlled by our Directors and their relatives to produce our air conditioners in an aggregate amount of RMB143.0 million, RMB258.6 million, RMB339.0 million, RMB77.2 million and RMB78.7 million, respectively.
For the years ended December 31, 2022, 2023, 2024 and the three months ended March 31, 2024 and 2025, we sold air conditioners to entities controlled by our Director and a company in which a relative of one of our Directors holds a 50% equity interest in an aggregate amount of RMB27.5 million, RMB42.1 million, RMB38.5 million, RMB6.3 million and RMB5.9 million, respectively.
Financial Information · p. 360
As of December 31, 2022 and 2023, the amounts due to related parties in non-trade nature amounted to RMB1,243.5 million and RMB1,494.1 million, respectively.
We entered into a general construction contract and an equipment procurement agreement with CCECC, a related party of our Group, in July 2021 and various construction project contracts with CCECC during the Track Record Period, with aggregate contract amount of HK$60.9 million, HK$171.5 million, HK$124.0 million and nil in 2022, 2023 and 2024 and the six months ended June 30, 2025, respectively.
Financial Information · p. 449
During the Track Record Period, we had outstanding loans from Jiangxi Copper HK and Ever Trillion pursuant to the 2019 Shareholder Loan Agreement and 2022 Shareholder Loan Agreement.
Financial Information · p. 450
We expect to settle all of our non-trade related party balances before the Listing.
The transactions involve sales of goods, including, waste lead slag for recycling, to Shuangdeng Tianpeng; and (ii) Purchases of products, including, recycled lead, from Shuangdeng Tianpeng (‘‘Tianpeng Transactions’’).
Financial Information · p. 389
The pricing and credit terms for Tianpeng Transactions are comparable those similar transactions with the Independent Third Parties and no favorable terms has been granted to/by Shuangdeng Tianpeng.
Financial Information · p. 389
Our Directors are of the view that the material related party transactions during the Track Record Period were conducted on an arm’s length basis.
We had borrowings from Mr. An and Mr. He, two of our Controlling Shareholders.
Financial Information · p. 415
Our Directors believe that our related party transactions set out in note 39 to the Accountants' Report in Appendix I were conducted on an arm's-length basis, and they would not distort our results of operations or cause our historical results to become not reflective of our future performance.
In 2022, 2023 and 2024, the revenue generated from these Related Channel Partners accounted for 3.7%, 5.0% and 7.3%, respectively, of the total revenue from the sales of AMR solutions.
Business · p. 281
Our contract terms with the Related Channel Partners are substantially the same as those with independent channel partners.
For the years ended December 31, 2022, 2023 and 2024, our purchases of goods from Nanjing Pharmaceutical Hubei Co., Ltd. amounted to RMB1.2 million, RMB1.3 million and RMB1.5 million, respectively.
Financial Information · p. 365
For the years ended December 31, 2022, 2023 and 2024, our rental payments for leases from Zhongshan Medical Investment amounted to RMB0.3 million, RMB0.3 million and RMB0.5 million, respectively.
Financial Information · p. 365
As of December 31, 2022, 2023 and 2024, we had non-trade dividends payable due to Zhongshan Medical Investment of nil, nil and RMB19.4 million, respectively, representing the dividends payable by us under our 2023 annual profit distribution plan.
As of December 31, 2022, 2023 and 2024 and as of April 30, 2025, we had loans from related parties of RMB1,027.6 million, RMB1,065.1 million, nil, and nil, respectively. These loans were mainly used for supplementing our working capital and optimizing our debt structure by repaying certain loans from financial institutions and were non-trade in nature.
Financial Information · p. 258
Our Directors confirm that these transactions were conducted in the ordinary course of our business, on an arm's length basis and with normal commercial terms between the relevant parties.
Our Directors have confirmed that all business transactions with related parties were conducted in the ordinary course of business and on an arm’s length basis.
Financial Information · p. 456
All non-trade balances will be settled prior to listing, other than certain transactions identified in Note 33 to the Accountants’ Report included in Appendix I.
Financial Information · p. 456
We also serve customers through collaboration and distribution agreements with our affiliate, bolttech, which is an insurtech platform operator and operates across over 35 markets.
During the Track Record Period, we conducted related party transactions with certain operators of our managed postpartum centers.
Financial Information · p. 416
Our loan of HK$3 million provided to our Hong Kong JV was converted from trade receivables, and will be repaid within five years from December 31, 2023.
Financial Information · p. 416
In the view of our Directors, our related party transactions during the Track Record Period were conducted on an arm's length basis.
As of December 31, 2022, 2023, and 2024, and April 30, 2025, our loans from related parties were RMB112.1 million, RMB195.2 million, RMB900.7 million, and RMB1,167.9 million, respectively.
Financial Information · p. 396
As of the Latest Practicable Date, our loans from related parties amounted to RMB220.7 million, all of which have been settled thereafter.
Financial Information · p. 396
Our Directors believe that our transactions with related parties during the Track Record Period were conducted on an arm's-length basis, and they did not distort our results of operations or make our historical results not reflective of our future performance.
As of December 31, 2023 and 2024, the balance with PharmaBlock Sciences (Nanjing), Inc. represented the unsettled research and development expenses, which was trade in nature.
Financial Information · p. 487
It is the view of our Directors that each of the above transactions during the Track Record Period (i) was conducted in the ordinary course of business and on an arm’s length basis and on normal commercial terms between the relevant parties, and (ii) did not distort our results of operations over the Track Record Period or made our historical results over the Track Record Period not reflective of our expectations for our future performance.
Financial Information · p. 487
As of the Latest Practicable Date, to the best of our Company’s knowledge, except for PharmaBlock, they are all Independent Third Parties.
As of December 31, 2022, 2023 and 2024, we recorded non-trade related amounts due from related parties of RMB180.6 million, RMB185.4 million and RMB86.8 million, respectively, and recorded non-trade related amounts due to related parties of RMB108.2 million, RMB17.0 million and nil, respectively.
Financial Information · p. 586
Regarding Huangshan Shoukang Hospital, which is one of our Managed Hospital and Health Service Center, from whom we recorded corresponding revenue of RMB67.2 million, RMB137.5 million and RMB111.6 million with respect to our supply of pharmaceuticals, medical equipment and consumables for the Track Record Period, respectively.
Business · p. 337
In particular, we recognized a net repayment of RMB96.8 million from Huangshan Shoukang Hospital for the year ended December 31, 2024.
During the Track Record Period, Jiaxing Haitian Small Loan, a subsidiary held as to 80% equity interest by Guangdong Haitian, provided some of our distributors with loans and financing using its own funds.
Business · p. 158
During the Track Record Period and up to the Latest Practicable Date, our distributors have not received any financing or financial assistance directly from us.
Business · p. 158
Our suppliers may select to use factoring service in connection with our procurements from them. During the Track Record Period, certain suppliers obtained such services from Haitian Commercial Factoring.